Generalized Anxiety Disorder Market Size and Forecast 2024-2033|Alkermes PLC, Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Bristol-Myers Squibb

Overview and Scope

Generalized anxiety disorder (GAD) is a mental health condition characterized by excessive and persistent worry, fear and anxiety about various aspects of life. It involves a broad range of concerns that can often feel uncontrollable and overwhelming. The treatment decisions change based on how significantly GAD is affecting a person’s ability to function in daily life.

Sizing and Forecast

The generalized anxiety disorder market size has grown steadily in recent years. It will grow from $7.51 billion in 2023 to $7.76 billion in 2024 at a compound annual growth rate (CAGR) of 3.3%.  The  growth in the historic period can be attributed to mental health awareness, pharmaceutical advances, cognitive-behavioral therapy (cbt), stressful lifestyle changes.

The generalized anxiety disorder market size is expected to see steady growth in the next few years. It will grow to $8.89 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%.  The growth in the forecast period can be attributed to digital mental health solutions, genetic research, integrated care models, global mental health awareness. Major trends in the forecast period include holistic approaches, cultural competence, early intervention, artificial intelligence (ai) in diagnosis.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/generalized-anxiety-disorder-global-market-report

Segmentation & Regional Insights

The generalized anxiety disorder market covered in this report is segmented –

1) By Type: Panic Disorder; Agoraphobia; Generalized Anxiety; Social Anxiety; Specific Phobia; Other Types

2) By Therapies: Interpersonal Therapy; Behavior Therapy; Cognitive Behavioral Therapy; Mindfulness Based Cognitive Therapy

3) By Device: Deep Brain Stimulation; Electroconvulsive Therapy; Transcranial Magnetic Stimulation; Vagus Nerve Stimulation

4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users

North America was the largest region in the generalized anxiety disorder market in 2023. The regions covered in generalized anxiety disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13039&type=smp

Major Driver Impacting Market Growth

The rising number of mental disorder cases in the healthcare industry is driving the growth of the generalized anxiety disorder market. A mental disorder, also known as a mental illness, refers to a wide range of conditions that affect a person’s thoughts, emotions, behaviors and overall mental well-being. Mental health disorders that commonly occur with generalized anxiety disorder include phobias, panic disorder, post-traumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD) and managing these conditions is crucial for individuals to maintain healthy relationships and improve their quality of life. For instance, in April 2023, Forbes Media LLC, a US-based media company, reported that in 2020, 21% of U.S. adults (52.9 million) reported mental illness. Furthermore, in March 2023, according to the National Alliance on Mental Illness, a US-based non-profit organization, 22.8% (57.8 million people) of U.S. adults experienced mental illness in 2021, which increased from previous years. Therefore, the rising number of mental disorder cases is expected to propel the growth of the generalized anxiety disorder market.

Key Industry Players

Major players in the generalized anxiety disorder market are  Alkermes PLC, Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Bristol-Myers Squibb, GlaxoSmithKline PLC, AstraZeneca PLC, Abbott Laboratories, 3M Company, Boehringer Ingelheim International GmbH, Johnson And Johnson Private Limited, Adobe Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Mylan N.V., Sumitomo Pharma Co. Ltd., Jazz Pharmaceuticals PLC, Forest Laboratories Inc., H. Lundbeck A/S, Shionogi and Company, Neurocrine Biosciences Inc., Actavis Pharmaceutical Company, Eli Lilly and Company, Noven Pharmaceuticals Inc., Mind Medicine Inc., Sage Therapeutics Inc., Bionomics Ltd., Recordati Rare Diseases SARL, VistaGen Therapeutics Inc.

The generalized anxiety disorder market report table of contents includes:

1. Executive Summary

2. Generalized Anxiety Disorder Market Characteristics

3. Generalized Anxiety Disorder Market Trends And Strategies

4. Generalized Anxiety Disorder Market – Macro Economic Scenario

5. Global Generalized Anxiety Disorder Market Size and Growt

.

.

.

26. South America Generalized Anxiety Disorder Market

27. Brazil Generalized Anxiety Disorder Market

28. Middle East Generalized Anxiety Disorder Market

29. Africa Generalized Anxiety Disorder Market

30. Generalized Anxiety Disorder Market Competitive Landscape And Company Profiles

Top Major Players:

• Alkermes PLC
• Pfizer Inc
• F. Hoffmann-La Roche AG
• Sanofi SA
• Bristol-Myers Squibb

Explore the trending research reports from TBRC:

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model